A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...
NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.
Neurotech Pharmaceuticals, Inc., an innovator in sustained drug delivery for chronic retinal diseases, today announced that the U.S. Food and Drug Administration (FDA), has extended the Prescription ...
The new PDUFA goal date for the biologics license application (BLA) of NT-501 (revakinagene taroretcel) as a treatment for Macular telangiectasia type 2 (MacTel) is March 18, 2025. "We are ...
GlobalData on MSN5d
FDA delays priority review of Neurotech’s eye cell therapy implantThe US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...
NT-501 implantation in patients with macular telangiectasia type 2 (MacTel2) is well-tolerated and correlates with a lower percentage of eyes with ellipsoid zone (EZ) loss at 72 to 108 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback